医学
梅尼埃病
无症状的
前庭诱发肌源性电位
回顾性队列研究
内淋巴水肿
听力学
疾病
外科
前庭系统
内科学
作者
Kimberley S. Noij,Barbara S. Herrmann,John J. Guinan,Steven D. Rauch
出处
期刊:Otology & Neurotology
[Ovid Technologies (Wolters Kluwer)]
日期:2019-12-01
卷期号:40 (10): 1346-1352
被引量:5
标识
DOI:10.1097/mao.0000000000002375
摘要
Objective: To investigate if the cervical vestibular evoked myogenic potential (cVEMP) is predictive for developing bilateral Menière's disease (MD). Study Design: Retrospective cohort study. Setting: Tertiary care center. Patients: Records of 71 patients previously diagnosed with unilateral MD at our institution who underwent cVEMP testing between 2002 and 2011 were screened. Intervention: Patients were contacted to answer a questionnaire to identify which patients had developed bilateral disease. Based on questionnaires and medical charts, 49 patients with a follow-up time of at least 5 years were included. The 49 originally asymptomatic ears are referred to as “study ears.” Previously reported cVEMP criteria (original criteria) applied to study-ear cVEMPs separated them into Menière -like and normal-like groups. Main Outcome Measure: The main purpose was to determine if previously obtained cVEMP thresholds and tuning ratios of unilateral MD patients could predict who develops bilateral disease. Results: From the 49 included patients, 12 developed bilateral disease (24.5%). The study ears characterized by original cVEMP criteria as Menière -like were significantly more likely to develop bilateral disease compared with the normal-like study ears. The original criteria predicted development of bilateral disease with a positive predictive value (PPV) and negative predictive value (NPV) of 58.3% and 86.5% respectively. ROC curves were used to revise cVEMP criteria for predicting the progression to bilateral disease. A revised criterion combining three cVEMP metrics, reached a PPV and NPV of 85.7% and 93.7%. Conclusion: cVEMP threshold and tuning in unilateral MD patients are predictive of which patients will develop bilateral disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI